Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase 3 2Phase 1/2 2Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Abiraterone Acetate 2rucaparib 1enzalutamide 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Metastatic Castration Resistant Prostate Cancer × Clear all
NCT02975934 2025-07-25

TRITON3

pharmaand GmbH

Phase 3 Completed
405 enrolled 34 charts 1 FDA
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04056754 2019-08-14

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Completed
268 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡